This Plain Language Summary of Publication article (PLSP) from Future Oncology describes the STARBOARD study’s initial safety lead-in phase compared two different encorafenib doses combined with binimetinib and pembrolizumab in patients with BRAF V600-mutant melanoma. This preliminary testing was conducted to establish the recommended dosage before advancing to further evaluation of this novel drug combination.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study’ and was published in the European Journal of Cancer.

Visit EJC using the link to read the original article.